J&J/Bayer’s Rivaroxaban Clinical Program Reports Few Liver Toxicity Cases
This article was originally published in The Pink Sheet Daily
Executive Summary
Oral Factor Xa inhibitor will be filed mid-year for prevention of venous thromboembolism in orthopedic surgery patients.